The future use of pathogen‐inactivated platelet concentrates
- 25 June 2003
- journal article
- Published by Wiley in Vox Sanguinis
- Vol. 85 (1) , 54-66
- https://doi.org/10.1046/j.1423-0410.2003.00315.x
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Broad‐spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistryVox Sanguinis, 2002
- Impact of donor arm skin disinfection on the bacterial contamination rate of platelet concentratesVox Sanguinis, 2002
- Making risk statements stickVox Sanguinis, 2002
- Diversion of first blood volume results in a reduction of bacterial contamination for whole‐blood collectionsVox Sanguinis, 2002
- Design of clinical trials to evaluate the efficacy of platelet transfusion: The euroSPRITE trial for components treated with helinx™ technologySeminars in Hematology, 2001
- Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasmaSeminars in Hematology, 2001
- Inactivation of infectious pathogens in labile blood components: meeting the challengeTransfusion Clinique et Biologique, 2001
- Evaluation of donor arm disinfection techniquesVox Sanguinis, 2001
- Functional Characteristics of S‐59 Photochemically Treated Platelet Concentrates Derived from Buffy CoatsVox Sanguinis, 2000
- Photochemical Inactivation of Bacteria and HIV in Buffy‐Coat‐Derived Platelet Concentrates under Conditions That Preserve in vitro Platelet FunctionVox Sanguinis, 2000